Prognostic impact of KRAS mutant type and MET amplification in ...

Targeting KRAS Mutant in Non-Small Cell Lung Cancer - Frontiers

As well, KRAS G12C-positive patients present a higher rate of metastasis at diagnosis compared with KRAS wild-type (i.e., 94.4% vs. 88.4%) (32).

KRAS and MET in non-small-cell lung cancer: two of the new kids on ...

Three different types of genetic alterations have been seen: fusion, amplification ... Prognostic impact of KRAS mutation subtypes in 677 patients ...

Clinical characteristic and survival outcomes of patients with ...

Approximatively 25%-30% of non-squamous NSCLC harbor a KRAS mutation (KRASm) in Western countries. These mutations mainly affect codons 12, 13, ...

KRAS G12C–Mutant Non–Small Cell Lung Cancer

The KRAS glycine-to-cysteine mutation (G12C) composes approximately 44% of KRAS mutations in non–small cell lung cancer, with mutant KRasG12C ...

Prognostic Role of KRAS G12C Mutation in Non-Small Cell Lung ...

KRAS G12C mutation (mKRAS G12C) is the most frequent KRAS point mutation in non-small cell lung cancer (NSCLC) and has been proven to be a ...

Impact of KRAS G12D subtype and concurrent pathogenic mutations ...

Mutations in the Kirsten rat sarcoma viral (KRAS) oncogene constitute a significant driver of lung adenocarcinoma, present in 10–40% of patients ...

Prognostic value of MET copy number gain in non-small-cell lung ...

The alterations of MET have been detected in non-small-cell lung cancer (NSCLC). However, the prognostic impact of MET gene copy number gain (CNG) has not been ...

Prognostic impact of KRAS G12C mutation in patients with NSCLC

1998, Guan et al. 2013. KRAS G12C in particular may be associated with worse prognosis compared with other KRAS mutations in resected stage I-III NSCLC (Finn et ...

The rapidly changing field of predictive biomarkers of non-small cell ...

In addition, other genetic abnormalities, such as EGFR mutations, modify the behavior of KRAS wild-type cases and affect prognosis [86].

BRAF and KRAS mutations in metastatic colorectal cancer

The BRAF mutation is also a strong indicator of poor prognosis in mCRC; the addition of an anti-EGFR agent had a detrimental effect on survival ...

KRAS as an emerging target in non-small cell lung cancer (NSCLC)

Mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) are one of the most common genomic alterations identified in solid tumors, especially lung cancer ...

impact of STK11, KRAS and TP53 mutations and co-mutations on ...

KRAS mutations are frequent alterations in NSCLC and KRAS-mutated disease represents a heterogeneous group. The subtype of KRAS mutation affects prognostic ...

GenesandCancer on X: "#PaperoftheDay: "Prognostic impact of ...

PaperoftheDay: "Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 ...

Analysis of 1115 Patients Tested for MET Amplification and Therapy ...

... type of BRAF mutation and MET amplification status was suggested. ... types may have confounded possible prognostic implications of MET amplification.

Targeting MET in NSCLC: An Ever-Expanding Territory

MET alterations in NSCLC mainly include MET exon 14 skipping mutations (METex14, 2%–4%),.

Prognostic impact of fibroblast growth factor receptor 2 gene ...

Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 ...

Overcoming KRAS-Mutant Lung Cancer - ASCO Publications

In the United States alone, approximately 50,000 individuals are newly diagnosed with KRAS-driven lung cancer annually. ... The prognosis for advanced KRAS-mutant ...

Concurrent MET copy number gain and KRAS mutation is a poor ...

Concurrent MET copy number gain and KRAS mutation is a poor prognostic factor in pancreatobiliary subtype ampullary cancers ... Authors: Mi Jung Kwon; Jeong Won ...

RBM10 Mutation as a Potential Negative Prognostic/Predictive ...

In subgroup analy- sis, of the 20 patients with rapid progression, 12 had additional driver mutations (4 EGFR, 6 KRAS, 1 MET ex14, and 1 ROS1).

Comprehensive pan-cancer genomic landscape of KRAS altered ...

... KRAS mutations but distinct from KRAS wild-type, though differences were observed in some tumor types for tumor mutational burden, PD-L1 ...